IQVIA (IQV) 10-Q 27 Jul 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 20, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Trading Symbol	Q
Entity Registrant Name	Quintiles Transnational Holdings Inc.
Entity Central Index Key	1,478,242
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		118,480,990

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Service revenues	$ 1,167,064	$ 1,074,366	$ 2,275,086	$ 2,104,340
Reimbursed expenses	385,609	369,161	767,672	686,780
Total revenues	1,552,673	1,443,527	3,042,758	2,791,120
Costs of revenue, service costs	740,639	683,845	1,441,205	1,345,672
Costs of revenue, reimbursed expenses	385,609	369,161	767,672	686,780
Selling, general and administrative	250,568	225,898	476,084	445,504
Restructuring costs	25,114	6,234	28,258	11,558
Income from operations	150,743	158,389	329,539	301,606
Interest income	(834)	(1,459)	(1,464)	(2,329)
Interest expense	22,483	25,487	48,442	50,827
Loss on extinguishment of debt		7,780		7,780
Other (income) expense, net	(2,803)	11,659	1,703	8,798
Income before income taxes and equity in (losses) earnings of unconsolidated affiliates	131,897	114,922	280,858	236,530
Income tax expense	36,810	31,700	79,387	67,788
Income before equity in (losses) earnings of unconsolidated affiliates	95,087	83,222	201,471	168,742
Equity in (losses) earnings of unconsolidated affiliates	(3,789)	1,725	(1,147)	2,636
Net income	91,298	84,947	200,324	171,378
Net (income) loss attributable to non-controlling interests	(4,539)	4	(6,897)	(29)
Net income attributable to Quintiles Transnational Holdings Inc.	$ 86,759	$ 84,951	$ 193,427	$ 171,349
Earnings per share attributable to common shareholders:
Basic	$ 0.73	$ 0.69	$ 1.62	$ 1.38
Diluted	$ 0.71	$ 0.67	$ 1.59	$ 1.35
Weighted average common shares outstanding:
Basic	119,464	123,834	119,456	124,169
Diluted	121,519	126,536	121,479	126,995

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 91,298	$ 84,947	$ 200,324	$ 171,378
Comprehensive income adjustments:
Unrealized gains (losses) on available-for-sale securities, net of income taxes of $49, $9, ($7) and ($95)	79	14	(11)	(151)
Unrealized (losses) gains on derivative instruments, net of income taxes of ($3,125), $327, ($7,462) and ($713)	(10,343)	3,444	(19,268)	(220)
Defined benefit plan adjustments, net of income taxes of $71			184
Foreign currency translation, net of income taxes of ($3,955), $146, ($4,803) and ($2,665)	(31,255)	13,007	(23,537)	(17,005)
Reclassification adjustments:
Losses on derivative instruments included in net income, net of income taxes of $650, $1,590, $2,431 and $3,246	2,941	3,502	7,501	7,338
Amortization of actuarial losses included in net income, net of income taxes of $78, $85, $151 and $168	145	147	281	287
Comprehensive income	52,865	105,061	165,474	161,627
Comprehensive loss (income) attributable to non-controlling interests	558	1	225	(29)
Comprehensive income attributable to Quintiles Transnational Holdings Inc.	$ 53,423	$ 105,062	$ 165,699	$ 161,598

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Unrealized gains (losses) on available-for-sale securities, income taxes	$ 49	$ 9	$ (7)	$ (95)
Unrealized (losses) gains on derivative instruments, income taxes	(3,125)	327	(7,462)	(713)
Defined benefit plan adjustments, income taxes			71
Foreign currency translation, income taxes	(3,955)	146	(4,803)	(2,665)
Losses on derivative instruments included in net income, income taxes	650	1,590	2,431	3,246
Amortization of actuarial losses included in net income, income taxes	$ 78	$ 85	$ 151	$ 168

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 955,684	$ 977,151
Restricted cash	3,489	2,478
Trade accounts receivable and unbilled services, net	1,257,427	1,165,749
Prepaid expenses	66,443	50,624
Deferred income taxes		100,978
Income taxes receivable	21,059	34,089
Investments in debt, equity and other securities	37,787
Other current assets and receivables	94,709	80,916
Total current assets	2,436,598	2,411,985
Property and equipment, net	189,630	188,393
Investments in debt, equity and other securities	7,852	32,911
Investments in unconsolidated affiliates	57,340	52,382
Goodwill	716,640	719,740
Other identifiable intangibles, net	352,755	368,106
Deferred income taxes	104,858	42,684
Deposits and other assets	97,125	110,115
Total assets	3,962,798	3,926,316
Current liabilities:
Accounts payable and accrued expenses	865,151	906,241
Unearned income	608,742	584,646
Income taxes payable	30,353	35,173
Current portion of long-term debt and obligations held under capital leases	48,503	48,513
Other current liabilities	47,539	19,603
Total current liabilities	1,600,288	1,594,176
Long-term debt and obligations held under capital leases, less current portion	2,397,834	2,419,293
Deferred income taxes	12,687	65,702
Other liabilities	180,690	182,826
Total liabilities	4,191,499	4,261,997
Commitments and contingencies
Shareholders’ deficit:
Common stock and additional paid-in capital, 300,000 shares authorized, $0.01 par value, 118,469 and 119,378 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	1,193	8,784
Accumulated deficit	(320,385)	(461,635)
Accumulated other comprehensive loss	(139,094)	(111,366)
Deficit attributable to Quintiles Transnational Holdings Inc.’s shareholders	(458,286)	(564,217)
Non-controlling interests	229,585	228,536
Total shareholders’ deficit	(228,701)	(335,681)
Total liabilities and shareholders’ deficit	$ 3,962,798	$ 3,926,316

CONDENSED CONSOLIDATED BALANCE6

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, shares authorized	300,000,000	300,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares issued	118,469,000	119,378,000
Common stock, shares outstanding	118,469,000	119,378,000

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating activities:
Net income	$ 200,324	$ 171,378
Adjustments to reconcile net income to cash provided by (used in) operating activities:
Depreciation and amortization	63,765	60,340
Amortization of debt issuance costs and discount	3,372	5,800
Amortization of accumulated other comprehensive loss on terminated interest rate swaps	3,100	1,651
Share-based compensation	18,765	20,321
Loss (earnings) from unconsolidated affiliates	5,612	(2,603)
Benefit from deferred income taxes	(2,646)	(375)
Excess income tax benefits from share-based award activities	(5,096)	(29,565)
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income	(81,230)	(177,494)
Change in other operating assets and liabilities	(53,234)	(63,023)
Net cash provided by (used in) operating activities	152,732	(13,570)
Investing activities:
Acquisition of property, equipment and software	(57,373)	(31,924)
Purchase of trading securities	(39,036)
Proceeds from corporate owned life insurance policies	20,938
Proceeds from sale of cost method investments	26,042
Investments in unconsolidated affiliates, net of payments received	(10,417)	(3,431)
Termination of interest rate swaps		(10,981)
Other	290	870
Net cash used in investing activities	(59,556)	(45,466)
Financing activities:
Proceeds from issuance of debt		2,248,500
Payment of debt issuance costs		(21,857)
Repayment of debt and principal payments on capital lease obligations	(24,831)	(2,035,051)
Stock issued under employee stock purchase and option plans	14,832	45,308
Repurchase of common stock	(97,637)	(250,000)
Excess income tax benefits from share-based award activities	5,096	29,565
Net cash (used in) provided by financing activities	(102,540)	16,465
Effect of foreign currency exchange rate changes on cash	(12,103)	(21,172)
Decrease in cash and cash equivalents	(21,467)	(63,743)
Cash and cash equivalents at beginning of period	977,151	867,358
Cash and cash equivalents at end of period	$ 955,684	$ 803,615

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP. Investments in Marketable Securities Investments in marketable securities are classified as either trading or available-for-sale and measured at fair market value. Realized and unrealized gains and losses on trading securities are included in other (income) expense, net on the accompanying condensed consolidated statements of income. Realized gains and losses on available-for-sale securities are included in other (income) expense, net on the accompanying condensed consolidated statements of income. Unrealized gains and losses, net of deferred income taxes, on available-for-sale securities are included in the accumulated other comprehensive income (loss) (“AOCI”) component of shareholders’ deficit until realized. Any gains or losses from the sales of investments or other-than-temporary declines in fair value are computed by specific identification. Recently Issued Accounting Standards Accounting pronouncement adopted In November 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance which removed the requirement that deferred income tax assets and liabilities be classified as either current or non-current in a classified statement of financial position and instead requires deferred income tax assets and liabilities to be classified as non-current. The Company adopted this new accounting guidance prospectively on January 1, 2016. Accounting pronouncements being evaluated In March 2016, the FASB issued new accounting guidance which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, and the classification of excess income tax benefits on the statement of cash flows. The Company expects to adopt this new accounting guidance as required on January 1, 2017. Under the new accounting guidance, excess income tax benefits related to share-based awards will be reflected as a reduction of income tax expense on the statements of income and as cash provided from operating activities. Under existing guidance, these tax benefits are reflected directly in additional paid-in capital and as cash provided from financing activities. The Company recognized $5.1 million of such income tax benefits in the six months ended June 30, 2016. The Company does not expect the adoption of this new accounting guidance to impact the recognition of its share-based compensation expense or its presentation of cash flows related to employee taxes paid for withheld shares. In February 2016, the FASB issued new accounting guidance which requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In January 2016, the FASB issued new accounting guidance which modifies how entities measure equity investments and present changes in the fair value of financial liabilities. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2017. Early adoption of the presentation guidance is permitted; however, early adoption of the recognition and measurement guidance is not permitted. The adoption of this new accounting guidance is not expected to have a material effect on the Company’s financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with clients. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to clients in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition including information about changes in assets and liabilities that result from contracts with clients. The new standard allows for either a retrospective or prospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new standard.

Employee Stock Compensation

Employee Stock Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Employee Stock Compensation	2. Employee Stock Compensation The Company granted the following number of share-based awards: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Stock options 39,400 53,200 783,700 976,900 Stock appreciation rights — — 25,200 176,200 Restricted stock units 84,065 10,389 373,836 237,210 Performance units — — 119,839 51,977 The Company had the following number of share-based awards outstanding: June 30, 2016 December 31, 2015 Stock options 6,794,700 6,647,999 Stock appreciation rights 530,476 530,701 Restricted stock units 664,709 359,553 Performance units 164,886 49,667 The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Expected volatility 26 – 29% 28 – 37% 26 – 30% 28 – 41% Weighted average expected volatility 26% 31% 28% 35% Expected dividends 0.0% 0.0% 0.0% 0.0% Expected term (in years) 3.6 – 6.6 3.7 – 6.7 3.6 – 6.6 3.7 – 6.7 Risk-free interest rate 0.80 – 1.23% 1.16 – 2.00% 0.80 – 1.57% 1.06 – 2.00% The Company issued 52,772 shares and 38,449 shares of common stock for purchases under its employee stock purchase plan during the six months ended June 30, 2016 and 2015, respectively. The Company recognized share-based compensation expense of $10.1 million and $10.7 million during the three months ended June 30, 2016 and 2015, respectively, and $18.8 million and $20.3 million during the six months ended June 30, 2016 and 2015, respectively.

Concentration of Credit Risk

Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2016
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	3. Concentration of Credit Risk No client accounted for 10% or more of consolidated service revenues for the three and six months ended June 30, 2016 or 2015.

Accounts Receivable and Unbille

Accounts Receivable and Unbilled Services	6 Months Ended
	Jun. 30, 2016
Receivables [Abstract]
Accounts Receivable and Unbilled Services	4. Accounts Receivable and Unbilled Services Accounts receivable and unbilled services consist of the following (in thousands): June 30, 2016 December 31, 2015 Trade: Billed $ 624,585 $ 553,652 Unbilled services 645,460 614,381 1,270,045 1,168,033 Allowance for doubtful accounts (12,618 ) (2,284 ) $ 1,257,427 $ 1,165,749

Investments-Debt, Equity and Ot

Investments-Debt, Equity and Other Securities	6 Months Ended
	Jun. 30, 2016
Investments Debt And Equity Securities [Abstract]
Investments-Debt, Equity and Other Securities	5. Investments – Debt, Equity and Other Securities The following is a summary of the Company’s investments in debt, equity and other securities (in thousands): June 30, 2016 December 31, 2015 Marketable trading securities $ 37,787 $ — Marketable available-for-sale securities $ 378 $ 395 Cost method investments 7,474 32,516 $ 7,852 $ 32,911 Marketable Securities Trading securities consist primarily of investments in mutual funds and are measured at fair value with realized and unrealized gains and losses recorded in other (income) expense, net on the accompanying condensed consolidated statements of income. Realized and unrealized gains, net of approximately $499,000 and $729,000 were recognized during the three and six months ended June 30, 2016, respectively. Available-for-sale securities consist of equity securities. Cost Method Investments On February 25, 2011, the Company and the Samsung Group entered into an agreement to form a joint venture intended to provide pharmaceutical contract manufacturing services in South Korea. In May 2016, the Company sold a portion of its ownership interest in the joint venture to the Samsung Group, at cost, in exchange for $26.0 million. As of June 30, 2016, the Company’s ownership interest in the joint venture was less than 1%.

Variable Interest Entities

Variable Interest Entities	6 Months Ended
	Jun. 30, 2016
Variable Interest Entity Disclosure [Abstract]
Variable Interest Entities	6. Variable Interest Entities As of June 30, 2016, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows (in thousands): Investments in Unconsolidated VIEs Maximum Exposure to Loss NovaQuest Pharma Opportunities Fund III, L.P. $ 40,077 $ 48,612 NovaQuest Pharma Opportunities Fund IV, L.P. 6,850 19,775 $ 46,927 $ 68,387 The Company has committed to invest up to $50 million as a limited partner in NovaQuest Pharma Opportunities Fund III, L.P. (“Fund III”). As of June 30, 2016, the Company has funded approximately $41.5 million and has approximately $8.5 million of remaining funding commitments. As of June 30, 2016 and December 31, 2015, the Company had a 10.9% ownership interest in Fund III. The Company’s maximum exposure to loss on Fund III is limited to its investment and remaining funding commitments. The Company has committed to invest up to $20 million as a limited partner in NovaQuest Pharma Opportunities Fund IV, L.P. (“Fund IV”). As of June 30, 2016, the Company has funded approximately $7.1 million and has approximately $12.9 million of remaining funding commitments. As of June 30, 2016 and December 31, 2015, the Company had a 2.3% ownership interest in Fund IV. The Company’s maximum exposure to loss on Fund IV is limited to its investment and remaining funding commitments. The Company has determined that Fund III and Fund IV (collectively “the Funds”) are VIEs but that the Company is not the primary beneficiary as it does not have a controlling financial interest in either of the Funds. Although the Company does not have a controlling financial interest in either of the Funds, the Company has determined that it has the ability to exercise significant influence. Accordingly, the Company accounts for its investments in the Funds under the equity method of accounting and records its pro rata share of the Funds’ earnings and losses in equity in (losses) earnings of unconsolidated affiliates on the accompanying condensed consolidated statements of income. The investment assets of unconsolidated VIEs are included in investments in and advances to unconsolidated affiliates

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	7. Goodwill The following is a summary of goodwill by segment for the six months ended June 30, 2016 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2015 $ 602,106 $ 117,634 $ 719,740 Impact of foreign currency fluctuations and other (7,243 ) 4,143 (3,100 ) Balance as of June 30, 2016 $ 594,863 $ 121,777 $ 716,640

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivatives	8. Derivatives As of June 30, 2016, the Company held the following derivative positions: (i) forward exchange contracts to protect against foreign exchange movements for certain forecasted foreign currency cash flows related to service contracts and (ii) interest rate swaps to hedge the exposure to variability in interest payments on variable interest rate debt. The Company does not use derivative financial instruments for speculative or trading purposes. As of June 30, 2016, the Company had 12 open foreign exchange forward contracts to hedge certain forecasted foreign currency cash flow transactions occurring in 2016 and the first three months of 2017 with notional amounts totaling $121.8 million. These contracts were executed to hedge the risk of the potential volatility in the cash flows resulting from fluctuations in currency exchange rates during the remainder of 2016 and the first three months of 2017. These transactions are accounted for as cash flow hedges, as such, the effective portion of the gain or loss on the contracts is recorded as unrealized gains (losses) on derivatives included in AOCI. For accounting purposes these hedges are deemed to be highly effective. As of June 30, 2016 and December 31, 2015, the Company had recorded gross unrealized losses of $12.2 million and $5.2 million, respectively, related to foreign exchange forward contracts. Upon expiration of the hedge instruments in 2016 and the first three months of 2017, the Company will reclassify the unrealized holding gains and losses on the derivative instruments included in AOCI into earnings. The unrealized losses are included in other current liabilities on the accompanying condensed consolidated balance sheets as of June 30, 2016 and December 31, 2015. On June 3, 2015, the Company entered into seven forward starting interest rate swaps with a notional value of $440.0 million in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. Interest on the swaps began accruing on June 30, 2016 and the interest rate swaps expire between March 31, 2017 and March 31, 2020. The critical terms of the interest rate swaps are substantially the same as those of the Company’s senior secured credit facilities, including quarterly interest settlements. These interest rate swaps are being accounted for as cash flow hedges as these transactions were executed to hedge the Company’s interest payments, and for accounting purposes these hedges are deemed to be highly effective. As such, changes in the fair value of these derivative instruments are recorded as unrealized gains (losses) on derivatives included in AOCI. The fair value of these interest rate swaps represents the present value of the anticipated net payments the Company will make to the counterparty, which, when they occur, are reflected as interest expense on the condensed consolidated statements of income. These payments, together with the variable rate of interest incurred on the underlying debt, result in a fixed rate of interest of 2.1% plus the applicable margin on the affected borrowings. These interest rate swaps will result in a total debt mix of approximately 50% fixed rate debt and 50% variable rate debt. The Company expects that $6.2 million of unrealized losses will be reclassified out of AOCI and will form the interest rate swap component of the 2.1% fixed rate of interest incurred over the next 12 months as the underlying net payments are settled. The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): Balance Sheet Classification June 30, 2016 December 31, 2015 Foreign exchange forward contracts Other current liabilities $ 12,232 $ 5,194 Interest rate swaps Other current liabilities $ 18,558 $ 5,698 The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Foreign exchange forward contracts $ (6,511 ) $ 8,078 $ (7,038 ) $ 6,389 Interest rate swaps (3,366 ) 785 (9,760 ) 3,262 Total $ (9,877 ) $ 8,863 $ (16,798 ) $ 9,651

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: · Level 1 — Quoted prices in active markets for identical assets or liabilities. · Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. · Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of June 30, 2016 (in thousands): Level 1 Level 2 Level 3 Total Assets: Trading securities $ 37,787 $ — $ — $ 37,787 Available-for-sale securities 378 — — 378 Total $ 38,165 $ — $ — $ 38,165 Liabilities: Foreign exchange forward contracts $ — $ 12,232 $ — $ 12,232 Interest rate swaps — 18,558 — 18,558 Contingent consideration — — 4,513 4,513 Total $ — $ 30,790 $ 4,513 $ 35,303 Below is a summary of the valuation techniques used in determining fair value: Marketable securities — The Company values trading and available-for-sale securities using the quoted market value of the securities held. Foreign exchange forward contracts — The Company values foreign exchange forward contracts using quoted market prices for identical instruments in less active markets or using other observable inputs. Interest rate swaps — The Company values interest rate swaps using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include revenue, net new business and operating forecasts and the probability of achieving the specific targets. The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the six months ended June 30 (in thousands): Contingent Consideration – Accounts Payable and Accrued Expenses 2016 2015 Balance as of January 1 $ 4,374 $ 1,452 Revaluations included in earnings 139 5,886 Balance as of June 30 $ 4,513 $ 7,338 The revaluations for the contingent consideration are recognized in other (income) expense, net on the accompanying condensed consolidated statements of income. Non-recurring Fair Value Measurements Certain assets are carried on the accompanying condensed consolidated balance sheets at cost and are not remeasured to fair value on a recurring basis. These assets include cost and equity method investments and loans that are written down to fair value for declines which are deemed to be other-than-temporary, and goodwill and identifiable intangible assets which are tested for impairment annually and when a triggering event occurs. As of June 30, 2016, assets carried on the balance sheet and not remeasured to fair value on a recurring basis totaling approximately $1,134.2 million and were identified as Level 3. These assets are comprised of cost and equity method investments of $64.8 million, goodwill of $716.6 million and other identifiable intangibles, net of $352.8 million. The estimated fair value of the Company’s long-term debt approximates its carrying value as of June 30, 2016 and December 31, 2015. The estimated fair value of the long-term debt is primarily based on rates in which the debt is traded among banks.

Shareholders' Deficit

Shareholders' Deficit	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Shareholders ' Deficit	10. Shareholders’ Deficit Equity Repurchase Program During the six months ended June 30, 2016, the Company repurchased 1,486,679 shares of its common stock under a previously approved equity repurchase program (the “Repurchase Program”) at an average market price per share of $65.67 for an aggregate purchase price of $97.6 million. From the plan’s inception in October 2013 through June 30, 2016, the Company has repurchased a total of $678.2 million of its securities under the Repurchase Program, consisting of $59.1 million of stock options and $619.1 million of common stock. As of June 30, 2016, the Company has remaining authorization to repurchase up to $46.8 million of its common stock under the Repurchase Program. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. Non-controlling Interests Below is a summary of non-controlling interests for the six months ended June 30 (in thousands): 2016 2015 Balance as of January 1 $ 228,536 $ 49 Investment by non-controlling interest 1,274 — Comprehensive income (loss): Net income 6,897 29 Foreign currency adjustments, net of income tax (7,122 ) — Balance as of June 30 $ 229,585 $ 78

Business Combinations

Business Combinations	6 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combinations	11. Business Combinations On May 3, 2016, the Company entered into a merger agreement with IMS Health Holdings, Inc. (“IMS Health”). If the merger agreement is approved by the companies’ respective stockholders and the other customary conditions to completing the merger are satisfied or waived, IMS Health will merge with and into the Company in a “merger of equals,” with the Company continuing as the surviving corporation (the “Surviving Corporation”) and the separate corporate existence of IMS Health ceasing. The merger will be accounted for using the acquisition method of accounting with the Company considered the accounting and legal acquirer. Upon completion of the merger, each share of IMS Health common stock outstanding immediately before the merger will be converted into the right to receive 0.3840 of a share of Surviving Corporation common stock. This exchange ratio will not be adjusted for changes in the market price or number of shares outstanding of either the Company’s common stock or IMS Health common stock between the date of signing the merger agreement and completion of the merger. IMS Health equity awards held by current employees and certain members of the IMS Health board of directors will be converted into Surviving Corporation equity awards after giving effect to the exchange ratio. The terms of the awards, including vesting provisions, will be substantially consistent to those of the historical IMS Health equity awards; provided that any awards subject to performance-based vesting criteria will be converted into Surviving Corporation awards that vest based solely upon continued service. If the merger agreement is terminated under certain circumstances, the Company or IMS Health, as applicable, will be required to pay the other a cash termination fee equal to $250 million. The merger is expected to close in the fourth quarter of 2016.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2016
Restructuring And Related Activities [Abstract]
Restructuring	12. Restructuring 2016 Plan During the first quarter of 2016, the Company’s Board of Directors (the “Board”) approved a restructuring plan for approximately $22 million, and in the second quarter of 2016 increased the approval to $41 million, primarily for severance and other exit costs, to align its resources and reduce overcapacity. These actions are expected to continue throughout 2016 and 2017, and are expected to consist of severance, facility closure and other exit-related costs. 2015 Plans During the first quarter of 2015 approved a restructuring plan for approximately $30.0 million to align the Company’s resources and reduce overcapacity. These actions are expected to continue throughout 2016, and are expected to consist of severance, facility closure and other exit-related costs. Also, in connection with consummating the joint venture transaction with Quest Diagnostics Incorporated, during the third quarter of 2015, a restructuring plan was approved to reduce facility overcapacity and eliminate redundant roles. These actions are expected to continue throughout 2016 and 2017, and are expected to consist of severance, facility closure and other exit-related costs of approximately $14.0 million. Since the start of this plan in 2015, the Company has recognized approximately $11.5 million of restructuring costs related to this plan for activities in the Product Development segment. The following amounts were recorded for the restructuring plans (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2015 $ 12,179 $ 1,385 $ 13,564 Expense, net of reversals 26,050 2,208 28,258 Payments (9,166 ) (508 ) (9,674 ) Foreign currency translation and other (1,785 ) 858 (927 ) Balance at June 30, 2016 $ 27,278 $ 3,943 $ 31,221 Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. The Company expects the majority of the restructuring accruals at June 30, 2016 will be paid in 2016 and 2017.

Employee Benefit Plans

Employee Benefit Plans	6 Months Ended
	Jun. 30, 2016
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	13. Employee Benefit Plans Defined Benefit Plans The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Service cost $ 4,477 $ 4,251 $ 8,631 $ 7,865 Interest cost 931 866 1,850 1,733 Expected return on plan assets (873 ) (861 ) (1,744 ) (1,714 ) Amortization of actuarial losses 223 232 432 455 $ 4,758 $ 4,488 $ 9,169 $ 8,339 Other As of June 30, 2016 and December 31, 2015, the Company had a severance accrual included in accounts payable and accrued expenses on the accompanying condensed consolidated balance sheets of $2.7 million and $3.3 million, respectively. The Company recognizes obligations associated with severance related to contractual termination benefits at fair value on the date that it is probable that the affected employees will be entitled to the benefit and the amount can reasonably be estimated. The severance accrual is related to cost reduction programs that will result in severance for approximately 270 positions. During the first six months of 2016, the Company recognized approximately $472,000 of net reversals related to these cost reduction programs in the Product Development segment, primarily as a result of affected individuals transferring into other positions within the Company. The Company expects the majority of the severance accrual at June 30, 2016 will be paid in 2017. The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2015 $ 3,337 Expense, net of reversals (472 ) Payments (90 ) Foreign currency translation (27 ) Balance at June 30, 2016 $ 2,748

Comprehensive Income

Comprehensive Income	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Comprehensive Income	14. Comprehensive Income Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Available-for-Sale Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2015 $ (116,830 ) $ (708 ) $ (13,992 ) $ (13,264 ) $ 33,428 $ (111,366 ) Other comprehensive (loss) income before reclassifications (21,218 ) (18 ) (26,730 ) 255 12,201 (35,510 ) Reclassification adjustments — — 9,932 432 (2,582 ) 7,782 Balance at June 30, 2016 $ (138,048 ) $ (726 ) $ (30,790 ) $ (12,577 ) $ 43,047 $ (139,094 ) Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands): Affected Financial Statement Three months ended June 30, Six months ended June 30, Reclassification Adjustments Line Item 2016 2015 2016 2015 Derivative instruments: Interest rate swaps Interest expense $ — $ 3,090 $ 3,100 $ 6,103 Foreign exchange forward contracts Service revenues 3,591 2,002 6,832 4,481 Total before income taxes 3,591 5,092 9,932 10,584 Income tax benefit 650 1,590 2,431 3,246 Total net of income taxes $ 2,941 $ 3,502 $ 7,501 $ 7,338 Defined benefit plans: Amortization of actuarial losses See Note 13 $ 223 $ 232 $ 432 $ 455 Total before income taxes 223 232 432 455 Income tax benefit 78 85 151 168 Total net of income taxes $ 145 $ 147 $ 281 $ 287

Segments

Segments	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Segments	15. Segments The following table presents the Company’s operations by reportable segment. The Company is managed through two reportable segments, Product Development and Integrated Healthcare Services. Product Development, which primarily serves biopharmaceutical clients engaged in research and development, provides clinical research and clinical trial services. Integrated Healthcare Services provides commercialization services to biopharmaceutical clients and research, analytics, real-world and late phase research, and other services to both biopharmaceutical clients and the broader healthcare market. Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of share-based compensation, merger and acquisition related costs, and expenses for corporate overhead functions such as senior leadership, finance, human resources, information technology, facilities and legal. The Company does not allocate restructuring charges to its segments. Information presented below is in thousands: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Service revenues Product Development $ 890,118 $ 786,397 $ 1,727,597 $ 1,535,926 Integrated Healthcare Services 276,946 287,969 547,489 568,414 Total service revenues 1,167,064 1,074,366 2,275,086 2,104,340 Costs of revenue, service costs Product Development 529,075 453,450 1,013,715 890,872 Integrated Healthcare Services 211,564 230,395 427,490 454,800 Total costs of revenue, service costs 740,639 683,845 1,441,205 1,345,672 Selling, general and administrative Product Development 174,093 156,777 337,646 311,885 Integrated Healthcare Services 39,559 38,845 76,250 76,767 General corporate and unallocated 36,916 30,276 62,188 56,852 Total selling, general and administrative 250,568 225,898 476,084 445,504 Income from operations Product Development 186,950 176,170 376,236 333,169 Integrated Healthcare Services 25,823 18,729 43,749 36,847 General corporate and unallocated (36,916 ) (30,276 ) (62,188 ) (56,852 ) Restructuring costs (25,114 ) (6,234 ) (28,258 ) (11,558 ) Total income from operations $ 150,743 $ 158,389 $ 329,539 $ 301,606 Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Depreciation and amortization expense Product Development $ 26,752 $ 23,553 $ 52,982 $ 47,429 Integrated Healthcare Services 4,272 5,171 8,529 10,379 General corporate and unallocated 1,017 1,287 2,254 2,532 Total depreciation and amortization expense $ 32,041 $ 30,011 $ 63,765 $ 60,340

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share	16. Earnings Per Share The following table presents the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share if they are subject to performance conditions or if the effect of including such share-based awards in the computation would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Shares subject to performance conditions 191 52 143 33 Shares subject to anti-dilutive share-based awards 1,588 1,130 1,438 1,079 Total shares excluded from diluted earnings per share 1,779 1,182 1,581 1,112 The vesting of performance units is contingent upon the achievement of certain performance targets. The performance units are not included in diluted earnings per share until the performance targets have been met. Share-based awards will have a dilutive effect under the treasury method when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of Quintiles Transnational Holdings Inc. and its subsidiaries (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015. The balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements of the Company but does not include all the disclosures required by GAAP.
Investments in Marketable Securities	Investments in Marketable Securities Investments in marketable securities are classified as either trading or available-for-sale and measured at fair market value. Realized and unrealized gains and losses on trading securities are included in other (income) expense, net on the accompanying condensed consolidated statements of income. Realized gains and losses on available-for-sale securities are included in other (income) expense, net on the accompanying condensed consolidated statements of income. Unrealized gains and losses, net of deferred income taxes, on available-for-sale securities are included in the accumulated other comprehensive income (loss) (“AOCI”) component of shareholders’ deficit until realized. Any gains or losses from the sales of investments or other-than-temporary declines in fair value are computed by specific identification.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Accounting pronouncement adopted In November 2015, the United States Financial Accounting Standards Board (“FASB”) issued new accounting guidance which removed the requirement that deferred income tax assets and liabilities be classified as either current or non-current in a classified statement of financial position and instead requires deferred income tax assets and liabilities to be classified as non-current. The Company adopted this new accounting guidance prospectively on January 1, 2016. Accounting pronouncements being evaluated In March 2016, the FASB issued new accounting guidance which simplifies several aspects of the accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax withholding requirements, and the classification of excess income tax benefits on the statement of cash flows. The Company expects to adopt this new accounting guidance as required on January 1, 2017. Under the new accounting guidance, excess income tax benefits related to share-based awards will be reflected as a reduction of income tax expense on the statements of income and as cash provided from operating activities. Under existing guidance, these tax benefits are reflected directly in additional paid-in capital and as cash provided from financing activities. The Company recognized $5.1 million of such income tax benefits in the six months ended June 30, 2016. The Company does not expect the adoption of this new accounting guidance to impact the recognition of its share-based compensation expense or its presentation of cash flows related to employee taxes paid for withheld shares. In February 2016, the FASB issued new accounting guidance which requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In January 2016, the FASB issued new accounting guidance which modifies how entities measure equity investments and present changes in the fair value of financial liabilities. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2017. Early adoption of the presentation guidance is permitted; however, early adoption of the recognition and measurement guidance is not permitted. The adoption of this new accounting guidance is not expected to have a material effect on the Company’s financial statements. In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with clients. The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to clients in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also will require expanded disclosures on revenue recognition including information about changes in assets and liabilities that result from contracts with clients. The new standard allows for either a retrospective or prospective approach to transition upon adoption. The new standard will be effective for annual reporting periods beginning after December 15, 2017. Early adoption is permitted for annual reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new standard on its consolidated financial statements, the date of adoption, and the transition approach to implement the new standard.

Employee Stock Compensation (Ta

Employee Stock Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Number of Share-Based Awards Granted and Outstanding	The Company granted the following number of share-based awards: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Stock options 39,400 53,200 783,700 976,900 Stock appreciation rights — — 25,200 176,200 Restricted stock units 84,065 10,389 373,836 237,210 Performance units — — 119,839 51,977 The Company had the following number of share-based awards outstanding: June 30, 2016 December 31, 2015 Stock options 6,794,700 6,647,999 Stock appreciation rights 530,476 530,701 Restricted stock units 664,709 359,553 Performance units 164,886 49,667
Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued	The Company used the following assumptions when estimating the value of the share-based compensation for stock options and stock appreciation rights issued as follows: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Expected volatility 26 – 29% 28 – 37% 26 – 30% 28 – 41% Weighted average expected volatility 26% 31% 28% 35% Expected dividends 0.0% 0.0% 0.0% 0.0% Expected term (in years) 3.6 – 6.6 3.7 – 6.7 3.6 – 6.6 3.7 – 6.7 Risk-free interest rate 0.80 – 1.23% 1.16 – 2.00% 0.80 – 1.57% 1.06 – 2.00%

Accounts Receivable and Unbil26

Accounts Receivable and Unbilled Services (Tables)	6 Months Ended
	Jun. 30, 2016
Receivables [Abstract]
Accounts Receivable and Unbilled Services	Accounts receivable and unbilled services consist of the following (in thousands): June 30, 2016 December 31, 2015 Trade: Billed $ 624,585 $ 553,652 Unbilled services 645,460 614,381 1,270,045 1,168,033 Allowance for doubtful accounts (12,618 ) (2,284 ) $ 1,257,427 $ 1,165,749

Investments-Debt, Equity and 27

Investments-Debt, Equity and Other Securities (Tables)	6 Months Ended
	Jun. 30, 2016
Investments Debt And Equity Securities [Abstract]
Summary of the Company's Investments in Debt, Equity and Other Securities	The following is a summary of the Company’s investments in debt, equity and other securities (in thousands): June 30, 2016 December 31, 2015 Marketable trading securities $ 37,787 $ — Marketable available-for-sale securities $ 378 $ 395 Cost method investments 7,474 32,516 $ 7,852 $ 32,911

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	6 Months Ended
	Jun. 30, 2016
Variable Interest Entity Disclosure [Abstract]
Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss	As of June 30, 2016, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows (in thousands): Investments in Unconsolidated VIEs Maximum Exposure to Loss NovaQuest Pharma Opportunities Fund III, L.P. $ 40,077 $ 48,612 NovaQuest Pharma Opportunities Fund IV, L.P. 6,850 19,775 $ 46,927 $ 68,387

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Goodwill by Segment	The following is a summary of goodwill by segment for the six months ended June 30, 2016 (in thousands): Integrated Product Healthcare Development Services Consolidated Balance as of December 31, 2015 $ 602,106 $ 117,634 $ 719,740 Impact of foreign currency fluctuations and other (7,243 ) 4,143 (3,100 ) Balance as of June 30, 2016 $ 594,863 $ 121,777 $ 716,640

Derivatives (Tables)

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2016
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments Designated as Hedges	The fair values of the Company’s derivative instruments designated as hedging instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table (in thousands): Balance Sheet Classification June 30, 2016 December 31, 2015 Foreign exchange forward contracts Other current liabilities $ 12,232 $ 5,194 Interest rate swaps Other current liabilities $ 18,558 $ 5,698
Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss)	The effect of the Company’s cash flow hedging instruments on other comprehensive income (loss) is summarized in the following table (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Foreign exchange forward contracts $ (6,511 ) $ 8,078 $ (7,038 ) $ 6,389 Interest rate swaps (3,366 ) 785 (9,760 ) 3,262 Total $ (9,877 ) $ 8,863 $ (16,798 ) $ 9,651

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured on a recurring basis as of June 30, 2016 (in thousands): Level 1 Level 2 Level 3 Total Assets: Trading securities $ 37,787 $ — $ — $ 37,787 Available-for-sale securities 378 — — 378 Total $ 38,165 $ — $ — $ 38,165 Liabilities: Foreign exchange forward contracts $ — $ 12,232 $ — $ 12,232 Interest rate swaps — 18,558 — 18,558 Contingent consideration — — 4,513 4,513 Total $ — $ 30,790 $ 4,513 $ 35,303
Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the six months ended June 30 (in thousands): Contingent Consideration – Accounts Payable and Accrued Expenses 2016 2015 Balance as of January 1 $ 4,374 $ 1,452 Revaluations included in earnings 139 5,886 Balance as of June 30 $ 4,513 $ 7,338

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Summary of Non-controlling Interests	Below is a summary of non-controlling interests for the six months ended June 30 (in thousands): 2016 2015 Balance as of January 1 $ 228,536 $ 49 Investment by non-controlling interest 1,274 — Comprehensive income (loss): Net income 6,897 29 Foreign currency adjustments, net of income tax (7,122 ) — Balance as of June 30 $ 229,585 $ 78

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2016
Restructuring And Related Activities [Abstract]
Summary of Amounts Recorded for Restructuring Plans	The following amounts were recorded for the restructuring plans (in thousands): Severance and Related Costs Exit Costs Total Balance at December 31, 2015 $ 12,179 $ 1,385 $ 13,564 Expense, net of reversals 26,050 2,208 28,258 Payments (9,166 ) (508 ) (9,674 ) Foreign currency translation and other (1,785 ) 858 (927 ) Balance at June 30, 2016 $ 27,278 $ 3,943 $ 31,221

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	6 Months Ended
	Jun. 30, 2016
Compensation And Retirement Disclosure [Abstract]
Summary of Components of Pension Expenses Related to Defined Benefit Plans	The following table summarizes the components of pension expense related to the Company’s defined benefit plans (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Service cost $ 4,477 $ 4,251 $ 8,631 $ 7,865 Interest cost 931 866 1,850 1,733 Expected return on plan assets (873 ) (861 ) (1,744 ) (1,714 ) Amortization of actuarial losses 223 232 432 455 $ 4,758 $ 4,488 $ 9,169 $ 8,339
Summary of Severance Associated with Cost Reduction Programs	The following amounts were recorded for the severance associated with cost reduction programs (in thousands): Balance at December 31, 2015 $ 3,337 Expense, net of reversals (472 ) Payments (90 ) Foreign currency translation (27 ) Balance at June 30, 2016 $ 2,748

Comprehensive Income (Tables)

Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Summary of Components of AOCI	Below is a summary of the components of AOCI (in thousands): Foreign Currency Translation Available-for-Sale Securities Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2015 $ (116,830 ) $ (708 ) $ (13,992 ) $ (13,264 ) $ 33,428 $ (111,366 ) Other comprehensive (loss) income before reclassifications (21,218 ) (18 ) (26,730 ) 255 12,201 (35,510 ) Reclassification adjustments — — 9,932 432 (2,582 ) 7,782 Balance at June 30, 2016 $ (138,048 ) $ (726 ) $ (30,790 ) $ (12,577 ) $ 43,047 $ (139,094 )
Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	Below is a summary of the (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item (in thousands): Affected Financial Statement Three months ended June 30, Six months ended June 30, Reclassification Adjustments Line Item 2016 2015 2016 2015 Derivative instruments: Interest rate swaps Interest expense $ — $ 3,090 $ 3,100 $ 6,103 Foreign exchange forward contracts Service revenues 3,591 2,002 6,832 4,481 Total before income taxes 3,591 5,092 9,932 10,584 Income tax benefit 650 1,590 2,431 3,246 Total net of income taxes $ 2,941 $ 3,502 $ 7,501 $ 7,338 Defined benefit plans: Amortization of actuarial losses See Note 13 $ 223 $ 232 $ 432 $ 455 Total before income taxes 223 232 432 455 Income tax benefit 78 85 151 168 Total net of income taxes $ 145 $ 147 $ 281 $ 287

Segments (Tables)

Segments (Tables)	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Reconciliation of Revenues and Income from Segments to Consolidated	Information presented below is in thousands: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Service revenues Product Development $ 890,118 $ 786,397 $ 1,727,597 $ 1,535,926 Integrated Healthcare Services 276,946 287,969 547,489 568,414 Total service revenues 1,167,064 1,074,366 2,275,086 2,104,340 Costs of revenue, service costs Product Development 529,075 453,450 1,013,715 890,872 Integrated Healthcare Services 211,564 230,395 427,490 454,800 Total costs of revenue, service costs 740,639 683,845 1,441,205 1,345,672 Selling, general and administrative Product Development 174,093 156,777 337,646 311,885 Integrated Healthcare Services 39,559 38,845 76,250 76,767 General corporate and unallocated 36,916 30,276 62,188 56,852 Total selling, general and administrative 250,568 225,898 476,084 445,504 Income from operations Product Development 186,950 176,170 376,236 333,169 Integrated Healthcare Services 25,823 18,729 43,749 36,847 General corporate and unallocated (36,916 ) (30,276 ) (62,188 ) (56,852 ) Restructuring costs (25,114 ) (6,234 ) (28,258 ) (11,558 ) Total income from operations $ 150,743 $ 158,389 $ 329,539 $ 301,606
Depreciation and Amortization Expense	Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Depreciation and amortization expense Product Development $ 26,752 $ 23,553 $ 52,982 $ 47,429 Integrated Healthcare Services 4,272 5,171 8,529 10,379 General corporate and unallocated 1,017 1,287 2,254 2,532 Total depreciation and amortization expense $ 32,041 $ 30,011 $ 63,765 $ 60,340

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Stock Options Excluded from Computation of Diluted Earnings Per Share	The following table presents the weighted average number of outstanding share-based awards not included in the computation of diluted earnings per share if they are subject to performance conditions or if the effect of including such share-based awards in the computation would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Shares subject to performance conditions 191 52 143 33 Shares subject to anti-dilutive share-based awards 1,588 1,130 1,438 1,079 Total shares excluded from diluted earnings per share 1,779 1,182 1,581 1,112

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2016USD ($)
Adoption of New Accounting Guidance [Member]
Summary Of Significant Accounting Policies [Line Items]
Excess income tax benefits recognized from share-based awards	$ 5.1

Employee Stock Compensation - S

Employee Stock Compensation - Schedule of Number of Share-Based Awards Granted and Outstanding (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	39,400	53,200	783,700	976,900
Stock options outstanding	6,794,700		6,794,700		6,647,999
Stock Appreciation Rights Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants			25,200	176,200
Equity Instruments Other than Options, Outstanding	530,476		530,476		530,701
Restricted Stock Units Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants	84,065	10,389	373,836	237,210
Equity Instruments Other than Options, Outstanding	664,709		664,709		359,553
Performance Units Granted [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity Instruments Other than Options, Grants			119,839	51,977
Equity Instruments Other than Options, Outstanding	164,886		164,886		49,667

Employee Stock Compensation - A

Employee Stock Compensation - Assumptions Used to Estimate Value of Share-Based Compensation for Stock Options and Stock Appreciation Rights Issued (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected volatility, Minimum	26.00%	28.00%	26.00%	28.00%
Expected volatility, Maximum	29.00%	37.00%	30.00%	41.00%
Weighted average expected volatility	26.00%	31.00%	28.00%	35.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Risk-free interest rate, Minimum	0.80%	1.16%	0.80%	1.06%
Risk-free interest rate, Maximum	1.23%	2.00%	1.57%	2.00%
Minimum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	3 years 7 months 6 days	3 years 8 months 12 days	3 years 7 months 6 days	3 years 8 months 12 days
Maximum [Member]
Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Method Used [Line Items]
Expected term (in years)	6 years 7 months 6 days	6 years 8 months 12 days	6 years 7 months 6 days	6 years 8 months 12 days

Employee Stock Compensation -41

Employee Stock Compensation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 10,100	$ 10,700	$ 18,765	$ 20,321
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued for purchases under employee stock purchase plan			52,772	38,449

Concentration of Credit Risk -

Concentration of Credit Risk - Additional Information (Detail) - Customer	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Risks And Uncertainties [Abstract]
Number of clients served	0	0	0	0

Accounts Receivable and Unbil43

Accounts Receivable and Unbilled Services - Accounts Receivable and Unbilled Services (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Trade:
Billed	$ 624,585	$ 553,652
Unbilled services	645,460	614,381
Trade accounts receivable and unbilled services, gross	1,270,045	1,168,033
Allowance for doubtful accounts	(12,618)	(2,284)
Trade accounts receivable and unbilled services, net	$ 1,257,427	$ 1,165,749

Investments - Debt, Equity and

Investments - Debt, Equity and Other Securities - Summary of the Company's Investments in Debt, Equity and Other Securities (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Investments Debt And Equity Securities [Abstract]
Marketable trading securities	$ 37,787
Marketable available-for-sale securities	378	$ 395
Cost method investments	7,474	32,516
Total	$ 7,852	$ 32,911

Investments - Debt, Equity an45

Investments - Debt, Equity and Other Securities - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	May 31, 2016	Jun. 30, 2016	Jun. 30, 2016
Investments Debt And Equity Securities [Line Items]
Realized and unrealized gains, net		$ 499,000	$ 729,000
Proceeds from sale of ownership interest in joint venture	$ 26,000,000
Maximum [Member]
Investments Debt And Equity Securities [Line Items]
Non controlling interest percentage in exchange of investment in joint venture		1.00%	1.00%

Variable Interest Entities - Su

Variable Interest Entities - Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss (Detail)	Jun. 30, 2016USD ($)
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	$ 46,927,000
Maximum Exposure to Loss	68,387,000
NovaQuest Pharma Opportunities Fund lll, L.P [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	40,077,000
Maximum Exposure to Loss	48,612,000
NovaQuest Pharma Opportunities Fund lV, L.P [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	6,850,000
Maximum Exposure to Loss	$ 19,775,000

Variable Interest Entities - Ad

Variable Interest Entities - Additional Information (Detail) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
NovaQuest Pharma Opportunities Fund lll, L.P [Member]
Variable Interest Entity [Line Items]
Committed to invest fund	$ 50
Commitment funded	41.5
Funding commitments	$ 8.5
Beneficial ownership in common stock	10.90%	10.90%
NovaQuest Pharma Opportunities Fund lV, L.P [Member]
Variable Interest Entity [Line Items]
Committed to invest fund	$ 20
Commitment funded	7.1
Funding commitments	$ 12.9
Beneficial ownership in common stock	2.30%	2.30%

Goodwill - Summary of Goodwill

Goodwill - Summary of Goodwill by Segment (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Goodwill [Line Items]
Beginning Balance	$ 719,740
Impact of foreign currency fluctuations and other	(3,100)
Ending Balance	716,640
Product Development [Member]
Goodwill [Line Items]
Beginning Balance	602,106
Impact of foreign currency fluctuations and other	(7,243)
Ending Balance	594,863
Integrated Healthcare Services [Member]
Goodwill [Line Items]
Beginning Balance	117,634
Impact of foreign currency fluctuations and other	4,143
Ending Balance	$ 121,777

Derivatives - Additional Inform

Derivatives - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2016USD ($)Derivative	Dec. 31, 2015USD ($)	Jun. 03, 2015USD ($)Agreement
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Agreement			7
Notional amount			$ 440,000,000
Interest swaps accrual beginning date	Jun. 30, 2016
Derivative fixed interest rate	2.10%
Interest rate cash flow hedge loss to be reclassified during next 12 months, net	$ 6,200,000
Senior Notes [Member] | Variable Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent	50.00%
Senior Notes [Member] | Fixed Rate Debt [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps effectively converted percent	50.00%
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Number of foreign exchange forward contracts | Derivative	12
Notional amount	$ 121,800,000
Losses related to these foreign exchange forward contracts	$ 12,200,000	$ 5,200,000
Expiration year of hedge instruments	2,016
Expiration description of hedge instruments	2016 and the first three months of 2017
Seven Interest Rate Swaps [Member] | Minimum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date	Mar. 31, 2017
Seven Interest Rate Swaps [Member] | Maximum [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date	Mar. 31, 2020

Derivatives - Summary of Fair V

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) - Designated as Hedging Instrument [Member] - Other Current Liabilities [Member] - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Foreign Exchange Forward Contracts [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$ 12,232	$ 5,194
Interest Rate Swaps [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	$ 18,558	$ 5,698

Derivatives - Effect of Cash Fl

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive Income (Loss) (Detail) - Derivatives Designated As Cash Flow Hedges [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ (9,877)	$ 8,863	$ (16,798)	$ 9,651
Foreign Exchange Forward Contracts [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	(6,511)	8,078	(7,038)	6,389
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ (3,366)	$ 785	$ (9,760)	$ 3,262

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Recurring Fair Value Measurements [Member] $ in Thousands	Jun. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 38,165
Fair value of liabilities	35,303
Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	12,232
Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	18,558
Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,513
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	38,165
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	30,790
Level 2 [Member] | Foreign Exchange Forward Contracts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	12,232
Level 2 [Member] | Interest Rate Swaps [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	18,558
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,513
Level 3 [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	4,513
Available-for-sale Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	378
Available-for-sale Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	378
Trading Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	37,787
Trading Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 37,787

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Accounts Payable and Accrued Expenses [Member] - Contingent Consideration [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance, Contingent Consideration	$ 4,374	$ 1,452
Revaluations included in earnings	139	5,886
Ending Balance, Contingent Consideration	$ 4,513	$ 7,338

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other identifiable intangibles, net	$ 352,755	$ 368,106
Non-recurring Fair Value Measurements [Member] | Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	1,134,200
Cost and equity method investments	64,800
Goodwill	716,600
Other identifiable intangibles, net	$ 352,800

Shareholders' Deficit - Additio

Shareholders' Deficit - Additional Information (Detail) - Equity Repurchase Program [Member] $ / shares in Units, $ in Millions	6 Months Ended	32 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)
Class Of Stock [Line Items]
Repurchase of stock, value		$ 678.2
Equity available for repurchase under the repurchase program	$ 46.8	46.8
Common Stock [Member]
Class Of Stock [Line Items]
Repurchase of stock, shares | shares	1,486,679
Repurchase of stock, average market price per share | $ / shares	$ 65.67
Repurchase of stock, value	$ 97.6	619.1
Stock Options [Member]
Class Of Stock [Line Items]
Repurchase of stock, value		$ 59.1

Shareholders' Deficit - Summary

Shareholders' Deficit - Summary of Non-controlling Interests (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Equity [Abstract]
Beginning Balance			$ 228,536	$ 49
Investment by non-controlling interest			1,274
Comprehensive income (loss):
Net income	$ 4,539	$ (4)	6,897	29
Foreign currency adjustments, net of income tax			(7,122)
Ending Balance	$ 229,585	$ 78	$ 229,585	$ 78

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - IMS Health Holdings, Inc. [Member] $ in Millions	6 Months Ended
	Jun. 30, 2016USD ($)
Business Acquisition [Line Items]
Merger agreement, date of merger agreement	May 3, 2016
Cash termination fee	$ 250
Merger agreement estimate closing period	fourth quarter of 2016
Common Stock [Member]
Business Acquisition [Line Items]
Merger agreement, convertible share conversion ratio	38.40%

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2016	Sep. 30, 2015	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 25,114,000		$ 6,234,000	$ 28,258,000	$ 11,558,000
Quest [Member]
Restructuring Cost and Reserve [Line Items]
Severance, facility closure and other exit-related costs		$ 14,000,000
2016 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved	$ 41,000,000			41,000,000		$ 22,000,000
2016 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs				21,600,000
2016 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs				1,700,000
2016 Plan [Member] | Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs				1,900,000
2015 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring plan approved							$ 30,000,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs				12,100,000
2015 Plan [Member] | Operating Segments [Member] | Product Development [Member] | Quest [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs				11,500,000
2015 Plan [Member] | Operating Segments [Member] | Integrated Healthcare Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs				8,900,000
2015 Plan [Member] | Corporate, Non-Segment [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs				$ 951,000

Restructuring - Summary of Amou

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance			$ 13,564
Expense, net of reversals	$ 25,114	$ 6,234	28,258	$ 11,558
Payments			(9,674)
Foreign currency translation and other			(927)
Restructuring reserves, ending balance	31,221		31,221
Severance and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance			12,179
Expense, net of reversals			26,050
Payments			(9,166)
Foreign currency translation and other			(1,785)
Restructuring reserves, ending balance	27,278		27,278
Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance			1,385
Expense, net of reversals			2,208
Payments			(508)
Foreign currency translation and other			858
Restructuring reserves, ending balance	$ 3,943		$ 3,943

Employee Benefit Plans - Summar

Employee Benefit Plans - Summary of Components of Pension Expenses Related to Defined Benefit Plans (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Compensation And Retirement Disclosure [Abstract]
Service cost	$ 4,477	$ 4,251	$ 8,631	$ 7,865
Interest cost	931	866	1,850	1,733
Expected return on plan assets	(873)	(861)	(1,744)	(1,714)
Amortization of actuarial losses	223	232	432	455
Total pension expense related to defined benefit plans	$ 4,758	$ 4,488	$ 9,169	$ 8,339

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2016USD ($)Position	Dec. 31, 2015USD ($)
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expenses payable	$ 2,748,000	$ 3,337,000
Number of positions expected to be eliminated | Position	270
Severance expense, net of reversals	$ (472,000)
Product Development [Member]
Employee Stock Purchase Plan And Cost Reduction Initiative Disclosure [Line Items]
Severance expense, net of reversals	$ (472,000)

Employee Benefit Plans - Summ62

Employee Benefit Plans - Summary of Severance Associated with Cost Reduction Programs (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Compensation And Retirement Disclosure [Abstract]
Severance expenses payable, opening balance	$ 3,337
Severance expense, net of reversals	(472)
Severance payments	(90)
Severance foreign currency translation	(27)
Severance expenses payable, ending balance	$ 2,748

Comprehensive Income - Summary

Comprehensive Income - Summary of Components of AOCI (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 33,428
Other comprehensive (loss) income before reclassifications, tax	12,201
Reclassification adjustments, tax	(2,582)
Ending Balance	43,047
Beginning Balance	(564,217)
Ending Balance	(458,286)
Foreign Currency Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(116,830)
Other comprehensive (loss) income before reclassifications, before tax	(21,218)
Ending Balance	(138,048)
Available-for-Sale Securities [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(708)
Other comprehensive (loss) income before reclassifications, before tax	(18)
Ending Balance	(726)
Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(13,992)
Other comprehensive (loss) income before reclassifications, before tax	(26,730)
Reclassification adjustments, before tax	9,932
Ending Balance	(30,790)
Defined Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(13,264)
Other comprehensive (loss) income before reclassifications, before tax	255
Reclassification adjustments, before tax	432
Ending Balance	(12,577)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(111,366)
Other comprehensive (loss) income before reclassifications, net of tax	(35,510)
Reclassification adjustments, net of tax	7,782
Ending Balance	$ (139,094)

Comprehensive Income - Summar64

Comprehensive Income - Summary of (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	$ 3,591	$ 5,092	$ 9,932	$ 10,584
Income tax benefit	650	1,590	2,431	3,246
Total net of income taxes	2,941	3,502	7,501	7,338
Amortization of actuarial losses	223	232	432	455
Total before income taxes	223	232	432	455
Income tax benefit	78	85	151	168
Total net of income taxes	145	147	281	287
Interest Rate Swaps [Member] | Interest Expense [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes		3,090	3,100	6,103
Foreign Exchange Forward Contracts [Member] | Service Revenues [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	$ 3,591	$ 2,002	$ 6,832	$ 4,481

Segments - Additional Informati

Segments - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2016Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segments - Operations by Report

Segments - Operations by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
Service revenues	$ 1,167,064	$ 1,074,366	$ 2,275,086	$ 2,104,340
Costs of revenue, service costs	740,639	683,845	1,441,205	1,345,672
Selling, general and administrative	250,568	225,898	476,084	445,504
Income from operations	150,743	158,389	329,539	301,606
Restructuring costs	(25,114)	(6,234)	(28,258)	(11,558)
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Service revenues	890,118	786,397	1,727,597	1,535,926
Costs of revenue, service costs	529,075	453,450	1,013,715	890,872
Selling, general and administrative	174,093	156,777	337,646	311,885
Income from operations	186,950	176,170	376,236	333,169
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Service revenues	276,946	287,969	547,489	568,414
Costs of revenue, service costs	211,564	230,395	427,490	454,800
Selling, general and administrative	39,559	38,845	76,250	76,767
Income from operations	25,823	18,729	43,749	36,847
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative	36,916	30,276	62,188	56,852
Income from operations	$ (36,916)	$ (30,276)	$ (62,188)	$ (56,852)

Segments - Depreciation and Amo

Segments - Depreciation and Amortization Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 32,041	$ 30,011	$ 63,765	$ 60,340
Operating Segments [Member] | Product Development [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	26,752	23,553	52,982	47,429
Operating Segments [Member] | Integrated Healthcare Services [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	4,272	5,171	8,529	10,379
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 1,017	$ 1,287	$ 2,254	$ 2,532

Earnings Per Share - Summary of

Earnings Per Share - Summary of Weighted-Average Outstanding Share-Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total shares excluded from diluted earnings per share	1,779	1,182	1,581	1,112
Performance Conditions [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total shares excluded from diluted earnings per share	191	52	143	33
Share-Based Awards [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total shares excluded from diluted earnings per share	1,588	1,130	1,438	1,079